Tumor cell enrichment by tissue suspension enables detection of mutations with low variant allele frequency and estimation of germline mutations.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 02 2022
Historique:
received: 31 08 2021
accepted: 07 02 2022
entrez: 23 2 2022
pubmed: 24 2 2022
medline: 22 3 2022
Statut: epublish

Résumé

Targeted sequencing offers an opportunity to select specific drugs for cancer patients based on alterations in their genome. However, accurate sequencing cannot be performed in cancers harboring diffuse tumor cells because of low tumor content. We performed tumor cell enrichment using tissue suspension of formalin-fixed, paraffin-embedded (FFPE) tissue sections with low tumor cell content. The enriched fractions were used to efficiently identify mutations by sequencing a target panel of cancer-related genes. Tumor-enriched and residual fractions were isolated from FFPE tissue sections of intestinal and diffuse gastric cancers harboring diffuse tumor cells and DNA of suitable quality was isolated for next-generation sequencing. Sequencing of a target panel of cancer-related genes using the tumor-enriched fraction increased the number of detectable mutations and variant allele frequency. Furthermore, mutation analysis of DNA isolated from tumor-enriched and residual fractions allowed us to estimate germline mutations without a blood reference. This approach of tumor cell enrichment will not only enhance the success rate of target panel sequencing, but can also improve the accuracy of detection of somatic mutations in archived specimens.

Identifiants

pubmed: 35194076
doi: 10.1038/s41598-022-06885-2
pii: 10.1038/s41598-022-06885-2
pmc: PMC8863826
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2953

Informations de copyright

© 2022. The Author(s).

Références

Sci Rep. 2017 Apr 4;7(1):641
pubmed: 28377632
Cancer Sci. 2019 Apr;110(4):1480-1490
pubmed: 30742731
Nat Commun. 2020 Jul 24;11(1):3715
pubmed: 32709844
Biomed Res. 2016;37(6):359-366
pubmed: 28003583
Pathobiology. 2012;79(3):154-61
pubmed: 22286119
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Gut. 2021 Mar;70(3):464-475
pubmed: 32532891
Biomed Res. 2016;37(6):367-379
pubmed: 28003584
Biomed Res. 2016;37(1):51-62
pubmed: 26912140
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Sci Rep. 2016 Feb 11;6:20944
pubmed: 26864208
Cancer Sci. 2020 Feb;111(2):687-699
pubmed: 31863614
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Bioinformatics. 2020 Apr 1;36(7):2173-2180
pubmed: 31750888
Biomed Res. 2018;39(3):159-167
pubmed: 29899191
Cancer Sci. 2019 Aug;110(8):2620-2628
pubmed: 31152682

Auteurs

Keiichi Hatakeyama (K)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan. k.hatakeyama@scchr.jp.

Koji Muramatsu (K)

Division of Pathology, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.

Takeshi Nagashima (T)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.
SRL Inc, Shinjuku-ku, Tokyo, 163-0409, Japan.

Yuichi Kawanishi (Y)

SRL & Shizuoka Cancer Center Collaborative Laboratories Inc, Sunto-gun, Shizuoka, 411-8777, Japan.

Ryutaro Fukumura (R)

SRL & Shizuoka Cancer Center Collaborative Laboratories Inc, Sunto-gun, Shizuoka, 411-8777, Japan.

Keiichi Ohshima (K)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.

Yuji Shimoda (Y)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.
SRL Inc, Shinjuku-ku, Tokyo, 163-0409, Japan.

Hirotsugu Kenmotsu (H)

Division of Genetic Medicine Promotion, Shizuoka Cancer Center, Sunto-gun, Shizuoka, 411-8777, Japan.

Tohru Mochizuki (T)

Medical Genetics Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.

Kenichi Urakami (K)

Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.

Yasuto Akiyama (Y)

Immunotheraphy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.

Takashi Sugino (T)

Division of Pathology, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, 411-8777, Japan.

Ken Yamaguchi (K)

Shizuoka Cancer Center, Sunto-gun, Shizuoka, 411-8777, Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH